Results 251 to 260 of about 33,638 (296)

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry. [PDF]

Hemasphere
Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Morrone L, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Boldrini V, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larràn A, Andreasson B, Vannucchi AM, Barbui T.   +17 more
europepmc   +1 more source

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis. [PDF]

Blood Adv
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Orvain C, Schroeder T, Bories C, Gurnari C, Badbaran A, Boyer F, Pagliuca S, Rautenberg C, Tavitian S, Pangiota V, Ianotto JC, Thol F, Cayssials E, Heuser M, Rubio MT, Cassinat B, Daltro de Oliveira R, Sauter C, Maciejewski JP, Reinhardt HC, Scott BL, Ugo V, Kröger N, Kiladjian JJ, Robin M.   +29 more
europepmc   +1 more source

Splenic Irradiation Preceding Allogeneic Hematopoietic Stem Cell Transplantation as a Possible Risk Factor of Sinusoidal Obstruction Syndrome: A Report of Three Cases. [PDF]

Case Rep Oncol
Shirane S, Yasuda H, Uchimura A, Mori Y, Inano T, Tsutsui M, Hamano Y, Ando M.   +7 more
europepmc   +1 more source

CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant [PDF]

Vannucchi, Alessandro M.
core   +1 more source

Educational Case: Essential thrombocythemia. [PDF]

Acad Pathol
Danielson DT, Muir JM.
europepmc   +1 more source

Prognostic significance of LOXL2 enzyme activity in primary myelofibrosis. [PDF]

Medicine (Baltimore)
Lv G, Lv W.
europepmc   +1 more source

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker. [PDF]

J Blood Med
Fadul A, Abdalla E, Mohamed A, Ali B, Elamin N, Alsayed AA, Al-Mashdali AF, Singh K, Mohamed SF.   +8 more
europepmc   +1 more source

Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy. [PDF]

Ann Hematol
Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, Beggiato E, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Scalzulli E, D'Agostino D, Caserta S, Nardo A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Palumbo GA, Breccia M, Elli EM, Bonifacio M.   +29 more
europepmc   +1 more source

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia. [PDF]

Haematologica
Patel AA, Rampal RK.
europepmc   +1 more source

New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease? [PDF]

Haematologica
Pasquier F, Pegliasco J, Martin JE, Marti S, Plo I.   +4 more
europepmc   +1 more source